Hypersensitivity to any component of this medication (for a complete listing of the components, see DOSAGE FORMS, COMPOSITION AND PACKAGING).
Active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal (see WARNINGS AND PRECAUTIONS).
Pregnancy and nursing women: Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). LIPITOR should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the possible harm. (If the patient becomes pregnant while taking LIPITOR, the drug should be discontinued immediately and the patient apprised of the potential harm to the fetus. Atherosclerosis being a chronic process, discontinuation of lipid metabolism regulating drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia (see PRECAUTIONS, Use in Pregnancy, Use in Nursing Mothers).
Concomitant treatment with hepatitis C antivirals telaprevir, boceprevir, glecaprevir/pibrentasvir, elbasvir/grazoprevir, simeprevir, velpatasvir/sofosbuvir, ledipasvir/sofosbuvir (see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS).
Concomitant treatment with the immunosuppressant cyclosporine (see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS).